Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
2.88
Dollar change
+0.50
Percentage change
21.01
%
Index- P/E- EPS (ttm)-0.10 Insider Own- Shs Outstand80.19M Perf Week19.50%
Market Cap232.82M Forward P/E- EPS next Y-0.10 Insider Trans- Shs Float- Perf Month9.09%
Income-8.19M PEG- EPS next Q-0.39 Inst Own0.16% Short Float- Perf Quarter5.49%
Sales56.10M P/S4.15 EPS this Y-463.48% Inst Trans-1.00% Short Ratio8.95 Perf Half Y15.66%
Book/sh0.78 P/B3.67 EPS next Y82.74% ROA-3.85% Short Interest0.09M Perf Year7.87%
Cash/sh1.26 P/C2.28 EPS next 5Y- ROE-14.23% 52W Range1.81 - 3.57 Perf YTD2.86%
Dividend Est.- P/FCF- EPS past 5Y- ROI-8.95% 52W High-19.33% Beta0.24
Dividend TTM- Quick Ratio3.84 Sales past 5Y31.77% Gross Margin- 52W Low59.12% ATR (14)0.17
Dividend Ex-Date- Current Ratio3.73 EPS Y/Y TTM86.00% Oper. Margin-43.20% RSI (14)63.55 Volatility6.23% 6.67%
Employees210 Debt/Eq0.77 Sales Y/Y TTM4.86% Profit Margin-14.60% Recom1.29 Target Price7.76
Option/ShortNo / Yes LT Debt/Eq0.60 EPS Q/Q84.65% Payout- Rel Volume5.80 Prev Close2.38
Sales Surprise28.04% EPS Surprise70.14% Sales Q/Q112.72% EarningsMar 21 BMO Avg Volume9.95K Price2.88
SMA2014.56% SMA5011.84% SMA2005.76% Trades Volume57,654 Change21.01%
Date Action Analyst Rating Change Price Target Change
Sep-03-21Upgrade SVB Leerink Mkt Perform → Outperform $7
Dec-15-20Downgrade SVB Leerink Outperform → Mkt Perform $7 → $5
Nov-24-20Initiated Goldman Neutral $4.75
Mar-22-24 11:33AM
Mar-21-24 02:00AM
Mar-19-24 02:00AM
Mar-14-24 02:00AM
Mar-06-24 01:00AM
01:00AM Loading…
01:00AM
Feb-21-24 01:00AM
Jan-12-24 01:00AM
Jan-04-24 01:00AM
12:59AM
Dec-19-23 01:00AM
Dec-18-23 01:00AM
Dec-11-23 01:00AM
Dec-10-23 01:00AM
Nov-27-23 01:00AM
10:36AM Loading…
Nov-15-23 10:36AM
Nov-14-23 01:00AM
Nov-07-23 01:00AM
Nov-03-23 02:00AM
Oct-27-23 01:00AM
Oct-19-23 01:00AM
Oct-16-23 01:00AM
Oct-09-23 01:00AM
Oct-05-23 01:00AM
Sep-22-23 01:00AM
Sep-14-23 01:00AM
Aug-29-23 01:00AM
Aug-10-23 01:00AM
Jul-11-23 01:00AM
Jul-07-23 01:00AM
01:00AM Loading…
Jun-26-23 01:00AM
01:00AM
Jun-16-23 01:00AM
Jun-12-23 01:00AM
Jun-10-23 01:00AM
Jun-08-23 01:00AM
01:00AM
Jun-07-23 01:00AM
May-26-23 01:00AM
May-23-23 01:00AM
May-15-23 01:00AM
May-12-23 04:00PM
May-10-23 01:00AM
May-09-23 01:00AM
May-03-23 01:00AM
01:00AM
Apr-26-23 04:50PM
Apr-21-23 01:00AM
Apr-18-23 01:00AM
Apr-07-23 01:00AM
Apr-06-23 01:00AM
Apr-03-23 01:00AM
Mar-23-23 02:00AM
Mar-20-23 02:00AM
Mar-16-23 02:00AM
Mar-13-23 02:00AM
Feb-21-23 01:00AM
Feb-07-23 01:00AM
Jan-25-23 01:00AM
Jan-16-23 01:00AM
Dec-19-22 01:00AM
Dec-12-22 11:35AM
Dec-10-22 10:00AM
Dec-09-22 01:00AM
Dec-01-22 01:00AM
Nov-14-22 01:00AM
Nov-07-22 01:00AM
Nov-04-22 02:00AM
Nov-02-22 02:00AM
Oct-20-22 01:00AM
Sep-23-22 01:00AM
Sep-15-22 08:00AM
01:00AM
Sep-08-22 01:00AM
Sep-05-22 01:00AM
Aug-23-22 01:00AM
Aug-08-22 01:00AM
Aug-01-22 08:48AM
01:00AM
Jul-28-22 01:00AM
Jul-21-22 01:00AM
Jun-23-22 01:00AM
Jun-03-22 01:00AM
May-20-22 04:00PM
May-11-22 01:00AM
May-10-22 01:00AM
12:55AM
May-03-22 05:22PM
01:00AM
Apr-29-22 01:00AM
Apr-08-22 01:00AM
Apr-05-22 01:00AM
Mar-24-22 02:00AM
Mar-17-22 02:00AM
Mar-03-22 01:00AM
Feb-15-22 01:00AM
Feb-04-22 01:00AM
Jan-24-22 01:00AM
Jan-05-22 01:00AM
Jan-04-22 01:00AM
Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Its product pipeline include Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Herve Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournie, and Francois Romagne on September 23, 1999 and is headquartered in Marseille, France.